These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34729560)

  • 1. A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike.
    Fu Y; Rezende E Mello JDF; Fleming BD; Renn A; Chen CZ; Hu X; Xu M; Gorshkov K; Hanson Q; Zheng W; Lee EM; Perera L; Petrovich R; Pradhan M; Eastman RT; Itkin Z; Stanley T; Hsu A; Dandey V; Gillette W; Taylor T; Ramakrishnan N; Perkins S; Esposito D; Oh E; Susumu K; Wolak M; Ferrer M; Hall MD; Borgnia MJ; Simeonov A
    bioRxiv; 2022 Mar; ():. PubMed ID: 34729560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike.
    Fu Y; da Fonseca Rezende E Mello J; Fleming BD; Renn A; Chen CZ; Hu X; Xu M; Gorshkov K; Hanson Q; Zheng W; Lee EM; Perera L; Petrovich R; Pradhan M; Eastman RT; Itkin Z; Stanley TB; Hsu A; Dandey V; Sharma K; Gillette W; Taylor T; Ramakrishnan N; Perkins S; Esposito D; Oh E; Susumu K; Wolak M; Ferrer M; Hall MD; Borgnia MJ; Simeonov A
    PLoS One; 2022; 17(8):e0272364. PubMed ID: 35947606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation of an escape-resistant SARS-CoV-2 neutralizing nanobody from a novel synthetic nanobody library.
    Dormeshkin D; Shapira M; Dubovik S; Kavaleuski A; Katsin M; Migas A; Meleshko A; Semyonov S
    Front Immunol; 2022; 13():965446. PubMed ID: 36189235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain.
    Ma H; Zeng W; Meng X; Huang X; Yang Y; Zhao D; Zhou P; Wang X; Zhao C; Sun Y; Wang P; Ou H; Hu X; Xiang Y; Jin T
    J Virol; 2021 Apr; 95(10):. PubMed ID: 33658349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
    Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
    Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.
    Lu Q; Zhang Z; Li H; Zhong K; Zhao Q; Wang Z; Wu Z; Yang D; Sun S; Yang N; Zheng M; Chen Q; Long C; Guo W; Yang H; Nie C; Tong A
    J Nanobiotechnology; 2021 Jan; 19(1):33. PubMed ID: 33514385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
    Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
    EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant.
    Verkhivker G
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational decomposition reveals reshaping of the SARS-CoV-2-ACE2 interface among viral variants expressing the N501Y mutation.
    Socher E; Conrad M; Heger L; Paulsen F; Sticht H; Zunke F; Arnold P
    J Cell Biochem; 2021 Dec; 122(12):1863-1872. PubMed ID: 34516024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
    Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
    Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering.
    Verkhivker G
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19.
    Esparza TJ; Chen Y; Martin NP; Bielefeldt-Ohmann H; Bowen RA; Tolbert WD; Pazgier M; Brody DL
    MAbs; 2022; 14(1):2047144. PubMed ID: 35289719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy.
    Zeng X; Li L; Lin J; Li X; Liu B; Kong Y; Zeng S; Du J; Xiao H; Zhang T; Zhang S; Liu J
    Antib Ther; 2020 Apr; 3(2):95-100. PubMed ID: 33912790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-nanobody combination increases their neutralizing activity against SARS-CoV-2 and nanobody H11-H4 is effective against Alpha, Kappa and Delta variants.
    Nguyen H; Li MS
    Sci Rep; 2022 Jun; 12(1):9701. PubMed ID: 35690632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants.
    Xu J; Xu K; Jung S; Conte A; Lieberman J; Muecksch F; Cetrulo Lorenzi JC; Park S; Wang Z; Tessarollo L; Bylund T; Chuang GY; Olia AS; Stephens T; Teng IT; Tsybovsky Y; Zhou T; Hatziioannou T; Bieniasz PD; Nussenzweig MC; Kwong PD; Casellas R
    bioRxiv; 2021 Mar; ():. PubMed ID: 33688659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike.
    Bracken CJ; Lim SA; Solomon P; Rettko NJ; Nguyen DP; Zha BS; Schaefer K; Byrnes JR; Zhou J; Lui I; Liu J; Pance K; ; Zhou XX; Leung KK; Wells JA
    bioRxiv; 2020 Aug; ():. PubMed ID: 32817948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corilagin and 1,3,6-Tri-
    Binette V; Côté S; Haddad M; Nguyen PT; Bélanger S; Bourgault S; Ramassamy C; Gaudreault R; Mousseau N
    Phys Chem Chem Phys; 2021 Jul; 23(27):14873-14888. PubMed ID: 34223589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
    Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
    mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.